Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Mathieu Beauregard

Showing results (11-20 of 63) with videos related to

Pageof 7
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 21, 2024
Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical CareIsabelle Laverdière, Gilbert Matte, Martin Darveau, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2011
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapyJean-Mathieu Beauregard, Michael S Hofman, Grace Kong, et al.
Cancers|August 27, 2021
PSMA Theranostics: Current Landscape and Future OutlookHanbo Zhang, Stella Koumna, Frédéric Pouliot, et al.
Clinical Nuclear Medicine|October 14, 2022
Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CTHanan Zahed, Jean-Mathieu Beauregard, Gad Abikhzer, et al.
EJNMMI Physics|May 17, 2020
Impact of dead time on quantitative <sup>177</sup>Lu-SPECT (QSPECT) and kidney dosimetry during PRRTAlessandro Desy, Guillaume F Bouvet, Andrea Frezza, et al.
Clinical Nuclear Medicine|June 9, 2015
Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the PancreasIoan-Andrei Iliuta, Jean-Mathieu Beauregard, Félix Couture, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 19, 2008
Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CTJean-Mathieu Beauregard, Etienne Croteau, Naseem Ahmed, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 21, 2011
Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT systemJean-Mathieu Beauregard, Michael S Hofman, Jucilene M Pereira, et al.
Physics in Medicine and Biology|July 10, 2019
Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a <sup>177</sup>Lu-DOTATATE patient studyWei Zhao, Pedro Luis Esquinas, Andrea Frezza, et al.
EJNMMI Physics|August 17, 2022
Impact of the dead-time correction method on quantitative <sup>177</sup>Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapyAlessandro Desy, Guillaume F Bouvet, Nancy Lafrenière, et al.
Pageof 7

Showing results (11-20 of 63) with videos related to

Sort By:
Pageof 7
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 21, 2024
Nuclear Pharmacy Training in the Era of Theranostics: Toward Meeting the Needs of Nuclear Medicine Patients for Comprehensive Pharmaceutical CareIsabelle Laverdière, Gilbert Matte, Martin Darveau, et al.
European Journal of Nuclear Medicine and Molecular Imaging|September 21, 2011
The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapyJean-Mathieu Beauregard, Michael S Hofman, Grace Kong, et al.
Cancers|August 27, 2021
PSMA Theranostics: Current Landscape and Future OutlookHanbo Zhang, Stella Koumna, Frédéric Pouliot, et al.
Clinical Nuclear Medicine|October 14, 2022
Differential Detection of Hepatic Metastases on 68 Ga-DOTATATE PET/CT and 177 Lu-DOTATATE SPECT/CTHanan Zahed, Jean-Mathieu Beauregard, Gad Abikhzer, et al.
EJNMMI Physics|May 17, 2020
Impact of dead time on quantitative <sup>177</sup>Lu-SPECT (QSPECT) and kidney dosimetry during PRRTAlessandro Desy, Guillaume F Bouvet, Andrea Frezza, et al.
Clinical Nuclear Medicine|June 9, 2015
Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the PancreasIoan-Andrei Iliuta, Jean-Mathieu Beauregard, Félix Couture, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 19, 2008
Assessment of human biodistribution and dosimetry of 4-fluoro-11beta-methoxy-16alpha-18F-fluoroestradiol using serial whole-body PET/CTJean-Mathieu Beauregard, Etienne Croteau, Naseem Ahmed, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|June 21, 2011
Quantitative (177)Lu SPECT (QSPECT) imaging using a commercially available SPECT/CT systemJean-Mathieu Beauregard, Michael S Hofman, Jucilene M Pereira, et al.
Physics in Medicine and Biology|July 10, 2019
Accuracy of kidney dosimetry performed using simplified time activity curve modelling methods: a <sup>177</sup>Lu-DOTATATE patient studyWei Zhao, Pedro Luis Esquinas, Andrea Frezza, et al.
EJNMMI Physics|August 17, 2022
Impact of the dead-time correction method on quantitative <sup>177</sup>Lu-SPECT (QSPECT) and dosimetry during radiopharmaceutical therapyAlessandro Desy, Guillaume F Bouvet, Nancy Lafrenière, et al.
Pageof 7